- Lilly plans a $3 billion facility in Katwijk, Netherlands, to expand oral medicine production.
- The site will create 500 permanent jobs and 1,500 construction jobs.
- Construction is expected to begin next year, pending government approvals.
- The facility will produce orforglipron, a GLP-1 receptor agonist for obesity.
Investment and Location
Eli Lilly and Company plans to invest $3 billion in a new manufacturing facility in Katwijk, Netherlands, located within the Leiden Bio Science Park. This project aims to expand Lilly's capacity for producing oral medicines.
Job Creation
The facility will create 500 high-wage jobs, including positions for engineers, scientists, operations personnel, and lab technicians. Additionally, 1,500 jobs are expected during the construction phase, which is set to begin next year.
Technological Advancements
The new site will feature advanced manufacturing technologies such as dock-to-dock automation, paperless manufacturing, process analytical technology, and spray-dried dispersion to enhance the absorption of oral medicines.
Product Focus
The facility will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, which the company plans to submit to global regulatory agencies for obesity treatment by the end of the year.
